[{"address1": "2656 State Street", "city": "Carlsbad", "state": "CA", "zip": "92008", "country": "United States", "phone": "619 728 4760", "website": "https://tyra.bio", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SN\u00c5P, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Dr. Todd  Harris Ph.D.", "age": 44, "title": "Co-Founder, President, CEO, Secretary, Treasurer & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1065650, "exercisedValue": 0, "unexercisedValue": 4803451}, {"maxAge": 1, "name": "Mr. Alan  Fuhrman", "age": 66, "title": "Chief Financial Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 763093, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hiroomi  Tada M.D., Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 816310, "exercisedValue": 0, "unexercisedValue": 2978274}, {"maxAge": 1, "name": "Mr. Daniel  Bensen", "age": 47, "title": "Co-Founder & COO", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 630800, "exercisedValue": 0, "unexercisedValue": 2216617}, {"maxAge": 1, "name": "Dr. Robert L. Hudkins Ph.D.", "age": 67, "title": "Chief Technology Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ronald V. Swanson Ph.D.", "age": 59, "title": "Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 536188, "exercisedValue": 0, "unexercisedValue": 298928}, {"maxAge": 1, "name": "Mr. Ali D. Fawaz J.D.", "title": "General Counsel", "fiscalYear": 2023, "totalPay": 629230, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sarah  Honig", "title": "Vice President of Corporate Development & Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Liz  Pagano", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Piyush R. Patel Ph.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 21.3, "open": 21.39, "dayLow": 20.6, "dayHigh": 21.39, "regularMarketPreviousClose": 21.3, "regularMarketOpen": 21.39, "regularMarketDayLow": 20.6, "regularMarketDayHigh": 21.39, "beta": 1.015, "forwardPE": -11.105264, "volume": 129049, "regularMarketVolume": 129049, "averageVolume": 171009, "averageVolume10days": 152030, "averageDailyVolume10Day": 152030, "bid": 20.93, "ask": 21.19, "bidSize": 100, "askSize": 100, "marketCap": 1124148992, "fiftyTwoWeekLow": 10.38, "fiftyTwoWeekHigh": 24.25, "fiftyDayAverage": 20.1214, "twoHundredDayAverage": 17.0548, "currency": "USD", "enterpriseValue": 755889536, "floatShares": 16199058, "sharesOutstanding": 52806100, "sharesShort": 2208392, "sharesShortPriorMonth": 2209618, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0418, "heldPercentInsiders": 0.04665, "heldPercentInstitutions": 0.98510003, "shortRatio": 14.04, "shortPercentOfFloat": 0.075100005, "bookValue": 7.131, "priceToBook": 2.958912, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -81441000, "trailingEps": -1.7, "forwardEps": -1.9, "pegRatio": 0.69, "enterpriseToEbitda": -7.955, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TYRA", "underlyingSymbol": "TYRA", "shortName": "Tyra Biosciences, Inc.", "longName": "Tyra Biosciences, Inc.", "firstTradeDateEpochUtc": 1631712600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c82a6c3c-220d-350b-9885-606667564179", "gmtOffSetMilliseconds": -14400000, "currentPrice": 21.1, "targetHighPrice": 33.0, "targetLowPrice": 22.0, "targetMeanPrice": 26.33, "targetMedianPrice": 25.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 373796000, "totalCashPerShare": 7.088, "ebitda": -95021000, "totalDebt": 6399000, "quickRatio": 36.187, "currentRatio": 36.464, "debtToEquity": 1.702, "returnOnAssets": -0.18571, "returnOnEquity": -0.26501, "freeCashflow": -35137248, "operatingCashflow": -62963000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]